Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case report, a 63-year-old man with an abnormally enlarged bladder holding 15 liters of urine was asymptomatic, emphasizing that chronic urinary retention can occur without symptoms and requires timely intervention to avoid complications.

This study supports the conclusion that the hormetic dose-response model is the most prevalent and fundamental model in biological and biomedical sciences, applicable to a wide range of clinical conditions.

This study found that finasteride competitively inhibits the enzyme AKR1D1 with low micromolar affinity but does not act as a mechanism-based inactivator.

This article reviews the role of hormones in human penis development and associated conditions due to hormonal imbalances, but reports no new findings, suggesting hormone replacement can manage some conditions.

In this case study, a male miniature dachshund with alopecia was diagnosed with estrogen-secreting Sertoli cell tumors and seminoma, with the alopecia resolving post-surgical removal of the tumor.

This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.

This animal study found that berberine may alleviate benign prostatic hyperplasia by reducing inflammation and oxidative stress through inhibition of the NF-κB signaling pathway.

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.

This abstract reports funding sources for ongoing research and does not present any study results.

This study found that high-dose pterostilbene potentially reduced prostate hyperplasia and had strong antioxidant effects in male rats with benign prostatic hyperplasia, suggesting it might be more effective than vitamin C and resveratrol in similar contexts.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

This paper discusses the effect of dutasteride on prostate cancer detection in men with benign prostatic hyperplasia but provides no new clinical results.

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

This review discusses the role of 5α-reductase in prostate development and BPH, and reports no new clinical results; ongoing trials are exploring dual isozyme inhibitors for improved treatment efficacy.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This study found that α-spinasterol treatment significantly reduced testosterone propionate-induced prostatic hyperplasia in rats, suggesting potential benefits for managing benign prostatic hyperplasia.

This study found that MENT is 10 times more potent than testosterone in suppressing gonadotropins and contributing to anabolism in monkeys, with a potentially wider therapeutic index for human androgen replacement and male contraception.

This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

In this study on testosterone-induced benign prostatic hyperplasia in rats, hydroxychloroquine significantly reduced prostate-related markers and enhanced therapeutic effects when combined with finasteride, suggesting potential as a new treatment approach.

In this study, the ethanol extract of Zapoteca portoricensis stem significantly reduced markers of testosterone-induced benign prostate hyperplasia in male albino rats without harming liver and kidney function.

This study found that ethanol extract of Syzygium aromaticum (clove) leaves significantly improved lipid profiles and increased body weight in testosterone-induced benign prostatic hyperplasia rats, suggesting potential anti-hyperlipidemic effects and modulation of body weight through metabolic activity.

In this study, researchers observed that Cuscuta reflexa extract mitigated inflammation and oxidative stress in testosterone-induced benign prostatic hypertrophy in Wistar rats, suggesting its potential as an adjunctive therapy for BPH.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

This study reported that high cholesterol levels were linked to increased prostate cancer risk, while selenium supplementation affected gene expression, suggesting nutritional and clinical factors might influence prostate cancer risk and biology.

This study found that aqueous extract of Pueraria mirifica, when administered to a rat model, significantly reduced prostate weight, prostatic index, and serum dihydrotestosterone levels, while also improving prostate histomorphology, suggesting its potential as an anti-BPH treatment.